217 related articles for article (PubMed ID: 15102368)
21. Targeting split vaccines to the endosome improves vaccination.
Wagner H; Heit A; Schmitz F; Bauer S
Curr Opin Biotechnol; 2004 Dec; 15(6):538-42. PubMed ID: 15560980
[TBL] [Abstract][Full Text] [Related]
22. IRAP identifies an endosomal compartment required for MHC class I cross-presentation.
Saveanu L; Carroll O; Weimershaus M; Guermonprez P; Firat E; Lindo V; Greer F; Davoust J; Kratzer R; Keller SR; Niedermann G; van Endert P
Science; 2009 Jul; 325(5937):213-7. PubMed ID: 19498108
[TBL] [Abstract][Full Text] [Related]
23. Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation.
Singh SK; Stephani J; Schaefer M; Kalay H; García-Vallejo JJ; den Haan J; Saeland E; Sparwasser T; van Kooyk Y
Mol Immunol; 2009 Dec; 47(2-3):164-74. PubMed ID: 19818504
[TBL] [Abstract][Full Text] [Related]
24. MHC class I-restricted exogenous presentation of a synthetic 102-mer malaria vaccine polypeptide.
Prato S; Maxwell T; Pinzón-Charry A; Schmidt CW; Corradin G; López JA
Eur J Immunol; 2005 Mar; 35(3):681-9. PubMed ID: 15688345
[TBL] [Abstract][Full Text] [Related]
25. Cross-presentation of a human tumor antigen delivered to dendritic cells by HSV VP22-mediated protein translocation.
Chhabra A; Mehrotra S; Chakraborty NG; Mukherji B; Dorsky DI
Eur J Immunol; 2004 Oct; 34(10):2824-33. PubMed ID: 15368298
[TBL] [Abstract][Full Text] [Related]
26. Virosomes for antigen and DNA delivery.
Daemen T; de Mare A; Bungener L; de Jonge J; Huckriede A; Wilschut J
Adv Drug Deliv Rev; 2005 Jan; 57(3):451-63. PubMed ID: 15560951
[TBL] [Abstract][Full Text] [Related]
27. Follicular and marginal zone B cells fail to cross-present MHC class I-restricted epitopes derived from viral particles.
Keller SA; von Allmen CE; Hinton HJ; Bauer M; Muntwiler S; Dietmeier K; Saudan P; Bachmann MF
J Immunol; 2009 May; 182(10):6261-6. PubMed ID: 19414779
[TBL] [Abstract][Full Text] [Related]
28. Cross-priming of cytotoxic T cells dictates antigen requisites for modified vaccinia virus Ankara vector vaccines.
Gasteiger G; Kastenmuller W; Ljapoci R; Sutter G; Drexler I
J Virol; 2007 Nov; 81(21):11925-36. PubMed ID: 17699574
[TBL] [Abstract][Full Text] [Related]
29. Recombinant antibodies with T-cell receptor-like specificity: novel tools to study MHC class I presentation.
Denkberg G; Reiter Y
Autoimmun Rev; 2006 Apr; 5(4):252-7. PubMed ID: 16697965
[TBL] [Abstract][Full Text] [Related]
30. [Mechanism of priming cytotoxic T cell response and strategy for enhancing DNA vaccine potency in DNA immunization].
Deng X; Cai M
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2003 Mar; 20(1):175-9. PubMed ID: 12744193
[TBL] [Abstract][Full Text] [Related]
31. The immunogenicity of CpG-antigen conjugates.
Wagner H
Adv Drug Deliv Rev; 2009 Mar; 61(3):243-7. PubMed ID: 19174176
[TBL] [Abstract][Full Text] [Related]
32. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens.
Heath WR; Belz GT; Behrens GM; Smith CM; Forehan SP; Parish IA; Davey GM; Wilson NS; Carbone FR; Villadangos JA
Immunol Rev; 2004 Jun; 199():9-26. PubMed ID: 15233723
[TBL] [Abstract][Full Text] [Related]
33. Enhanced generation of cytotoxic T lymphocytes by increased cytosolic delivery of MHC class I epitope fused to mouse heat shock protein 70 via polyhistidine conjugation.
Takemoto S; Nishikawa M; Otsuki T; Yamaoka A; Maeda K; Ota A; Takakura Y
J Control Release; 2009 Apr; 135(1):11-8. PubMed ID: 19100299
[TBL] [Abstract][Full Text] [Related]
34. Human CD14 is an efficient target for recombinant immunoglobulin vaccine constructs that deliver T cell epitopes.
Tunheim G; Schjetne KW; Fredriksen AB; Sandlie I; Bogen B
J Leukoc Biol; 2005 Mar; 77(3):303-10. PubMed ID: 15576418
[TBL] [Abstract][Full Text] [Related]
35. Antigen bias in T cell cross-priming.
Wolkers MC; Brouwenstijn N; Bakker AH; Toebes M; Schumacher TN
Science; 2004 May; 304(5675):1314-7. PubMed ID: 15166378
[TBL] [Abstract][Full Text] [Related]
36. DNA fusion gene vaccines.
Holst PJ; Bassi MR; Thomsen AR; Christensen JP
Curr Opin Mol Ther; 2010 Feb; 12(1):47-54. PubMed ID: 20140816
[TBL] [Abstract][Full Text] [Related]
37. Antigen processing: a critical factor in rational vaccine design.
Yewdell JW; Bennink JR
Semin Hematol; 1993 Oct; 30(4 Suppl 4):26-32; discussion 33-4. PubMed ID: 8303307
[TBL] [Abstract][Full Text] [Related]
38. MHC class I-associated presentation of exogenous peptides is not only enhanced but also prolonged by linking with a C-terminal Lys-Asp-Glu-Leu endoplasmic reticulum retrieval signal.
Wang L; Wu YZ; Chen A; Zhang JB; Yang Z; Niu W; Geng M; Ni B; Zhou W; Zou LY; Jiang M
Eur J Immunol; 2004 Dec; 34(12):3582-94. PubMed ID: 15495159
[TBL] [Abstract][Full Text] [Related]
39. Enhancement of dendritic cell-based vaccine potency by anti-apoptotic siRNAs targeting key pro-apoptotic proteins in cytotoxic CD8(+) T cell-mediated cell death.
Kim JH; Kang TH; Noh KH; Bae HC; Kim SH; Yoo YD; Seong SY; Kim TW
Immunol Lett; 2009 Jan; 122(1):58-67. PubMed ID: 19135479
[TBL] [Abstract][Full Text] [Related]
40. Dynamic quantification of MHC class I-peptide presentation to CD8+ T cells via intracellular cytokine staining.
Pang KC; Wei JQ; Chen W
J Immunol Methods; 2006 Apr; 311(1-2):12-8. PubMed ID: 16516224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
